

Article

Lymphoma-Associated Biomarkers Are Increased in Current Smokers in Twin Pairs Discordant for Smoking

Jun Wang ¹, David V. Conti ^{1,2}, Marta Epeldegui ³ , Miina Ollikainen ⁴, Rachel F. Tyndale ⁵ ,
Amie Eunah Hwang ¹, Larry Magpantay ³, Thomas McCulloch Mack ^{1,6}, Otoniel Martinez-Maza ^{3,7,8},
Jaakko Kaprio ^{4,9}  and Wendy Cozen ^{10,11,12,*}

- ¹ Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; jun.wang@med.usc.edu (J.W.); dconti@usc.edu (D.V.C.); amiehwan@usc.edu (A.E.H.); tmack@med.usc.edu (T.M.M.)
- ² Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
- ³ Department of Obstetrics and Gynecology, AIDS Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA; MEpeldegui@mednet.ucla.edu (M.E.); LMagpantay@mednet.ucla.edu (L.M.); OMartinez@mednet.ucla.edu (O.M.-M.)
- ⁴ Department of Public Health, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland; miina.ollikainen@helsinki.fi (M.O.); jaakko.kaprio@helsinki.fi (J.K.)
- ⁵ Centre for Addiction and Mental Health, Departments of Pharmacology & Toxicology, and Psychiatry, University of Toronto, and Campbell Family Mental Health Research Institute, Toronto, ON M5S 1A8, Canada; r.tyndale@utoronto.ca
- ⁶ Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
- ⁷ Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA
- ⁸ Microbiology and Immunology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
- ⁹ Institute for Molecular Medicine, University of Helsinki, 00014 Helsinki, Finland
- ¹⁰ Department of Medicine, Division of Hematology-Oncology, School of Medicine, University of California Irvine, Orange, CA 92868, USA
- ¹¹ Department of Pathology, School of Medicine, University of California Irvine, Orange, CA 92868, USA
- ¹² Department of Epidemiology, School of Population Health, Susan and Henry Samueli College of Health Sciences, University of California Irvine, Irvine, CA 92697, USA
- * Correspondence: wcozen@hs.uci.edu; Tel.: +714-456-5153; Fax: +714-456-2242



Citation: Wang, J.; Conti, D.V.; Epeldegui, M.; Ollikainen, M.; Tyndale, R.F.; Hwang, A.E.; Magpantay, L.; Mack, T.M.; Martinez-Maza, O.; Kaprio, J.; et al. Lymphoma-Associated Biomarkers Are Increased in Current Smokers in Twin Pairs Discordant for Smoking. *Cancers* **2021**, *13*, 5395. <https://doi.org/10.3390/cancers13215395>

Academic Editors: Ajay Pratap Singh and Seema Singh

Received: 17 September 2021
Accepted: 19 October 2021
Published: 27 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Simple Summary: Smoking is associated with a moderate increased risk of Hodgkin and follicular lymphoma. To help understand why, we examined lymphoma-related biomarker levels among 134 smoking and non-smoking twins (67 pairs) ascertained from the Finnish Twin Cohort. We validated self-reported smoking history by measuring serum cotinine, a metabolite of nicotine, from previously collected frozen serum samples. In total, 27 immune biomarkers were assayed using the Luminex Multiplex platform (R & D Systems). We found that four immune response biomarkers were higher and one was lower among smoking compared to non-smoking twins. The strongest association was observed for CCL17/TARC, a biomarker elevated in Hodgkin lymphoma patients. Immune biomarker levels were similar in former smokers and non-smokers. Current smoking may increase levels of immune proteins that could partially explain the association between smoking and risk of certain lymphomas.

Abstract: Smoking is associated with a moderate increased risk of Hodgkin and follicular lymphoma. To understand why, we examined lymphoma-related biomarker levels among 134 smoking and non-smoking twins (67 pairs) ascertained from the Finnish Twin Cohort. Previously collected frozen serum samples were tested for cotinine to validate self-reported smoking history. In total, 27 immune biomarkers were assayed using the Luminex Multiplex platform (R & D Systems). Current and non-current smokers were defined by a serum cotinine concentration of >3.08 ng/mL and ≤3.08 ng/mL, respectively. Associations between biomarkers and smoking were assessed using linear mixed models to estimate beta coefficients and standard errors, adjusting for age, sex and twin

pair as a random effect. There were 55 never smokers, 43 current smokers and 36 former smokers. CCL17/TARC, sgp130, haptoglobin, B-cell activating factor (BAFF) and monocyte chemoattractant protein-1 (MCP1) were significantly ($p < 0.05$) associated with current smoking and correlated with increasing cotinine concentrations ($P_{\text{trend}} < 0.05$). The strongest association was observed for CCL17/TARC ($P_{\text{trend}} = 0.0001$). Immune biomarker levels were similar in former and never smokers. Current smoking is associated with increased levels of lymphoma-associated biomarkers, suggesting a possible mechanism for the link between smoking and risk of these two B-cell lymphomas.

Keywords: TARC/CCL17; BAFF; MCP1; spg130; smoking; Hodgkin lymphoma; follicular lymphoma; twins; chemokines; cytokines; biomarkers

1. Introduction

Smoking is an established risk factor for multiple epithelial cancers [1]. Accumulating evidence suggests that it may also increase the risk of some hematological cancers. Cigarette smoking is associated with a modestly increased overall risk of Hodgkin lymphoma (HL), but approximately 60–80% increased risk for certain HL subtypes, including mixed cellularity HL and Epstein–Barr virus (EBV)-positive HL [2,3]. It is also a risk factor for follicular lymphoma, one of the common subtypes of non-Hodgkin Lymphoma (NHL) [4]. However, the exact mechanism underlying the association between cigarette smoking and increased lymphoma risk remains largely unexplained. Cigarette smoking can alter immune responses by producing Th2 cytokines, including interleukin [IL]4 (IL4) and IL13 [5], which may protect B-cell tumors against apoptosis [6]. IL13 levels are also higher among infants exposed to prenatal maternal smoking compared to those without smoking exposure [7]. In a convenience sample, Byron and colleagues showed that phytohemagglutinin (PHA) induced IL4 production in cultured peripheral blood mononuclear cells (PBMC) of smokers was significantly higher compared to that in non-smokers [8]. We used the same laboratory method applied to a set of monozygotic (MZ) twin pairs with varying levels of smoking, naturally matched on genetics, early life and parental smoke exposure, and found that serum IL13 supernatant levels from similarly PHA-stimulated PBMCs were significantly higher among smoking compared to non-smoking twins [9]. PHA-stimulation was used to obtain measurable levels of these cytokines, which are often undetectable and unstable in serum. The method artificially increased levels of these Th2 cytokines and thus physiological responses were not evaluated. A recent tobacco industry-funded study examined leukocyte subset counts by flow cytometry and serum levels of inflammatory cytokines among Italian smoking-discordant twin pairs and found differences in leukocyte counts but not serum cytokine levels [10]. They did not examine soluble immune biomarkers related to HL or FL and did not account for smoking duration or current vs. former smoking.

Altered immunity plays a critical role in both HL and NHL risk and pathogenesis [11–14], in which both immune deficiency and immune activation are associated with increased risk. Pre-diagnostic serum levels of markers of B-cell activation (i.e., sCD23, sCD27, sCD30 and sCXCL13), even as early as 9 years before diagnosis, were significantly associated with increased NHL risk in the Women’s Health Initiative Cohort study [15]. CCL17/TARC, CD30 and IL6 are among the immune-mediating molecules associated with HL prognosis and pathogenesis [16–18].

In addition, microbial translocation of bacterial molecules (e.g., endotoxin from Gram-negative bacterial cell walls) from the gut to bloodstream through a leaky intestinal epithelium results in excessive macrophage stimulation, which, in turn, induces B-cell stimulation, with low levels of endotoxin promoting B-cell induced CD4+ proliferation and high levels promoting CD8+ proliferation [19]. Endotoxin induces B-cell activating factor (BAFF), which is associated with lymphomagenesis [20]. We measured serum markers of microbial translocation (haptoglobin, lipopolysaccharide-binding protein (LPB), fatty acid binding

protein 2 (FABP2) and soluble CD14) and macrophage activation (BAFF, CCL17/TARC, monocyte chemoattractant protein-1 (MCP1), and the soluble form of the 130 kDa IL6 receptor (s13gp0)) in a cohort of HIV-positive patients and found that higher levels at baseline predicted the development of NHL [21]. Because smoking disrupts the alveolar–blood barrier through physical assaults of heat and through a variety of chemical exposures in tobacco, microbial translocation occurs at this site as well [22], and thus could conceivably be a mechanism that increases risk of NHL or HL by allowing endotoxins to enter the bloodstream to promote immune dysregulation.

To better understand the association between smoking and lymphoma risk, we sought to characterize immune markers related to lymphoma in a sample of MZ from the Finnish Twin Cohort [23] study with varying levels of cigarette smoking. Twins as participants bring advantages to the study of environmental and lifestyle exposures because they are matched in terms of genetics and early life environment and therefore mitigate potential confounding by these factors when comparing unrelated cases and controls.

2. Materials and Methods

2.1. Study Population

In total, 67 MZ twin pairs (134 individual twins) with no major health conditions such as cardiovascular disease or cancer were identified from three longitudinal population-based Finnish twin cohorts designed to investigate genetic and environment determinants of common diseases and related behavioral risk factors. The older Finnish Twin Cohort consists of adult twins born from 1938 to 1957, the FinnTwin12 [24] comprises twins born from 1983 to 1987 and the FinnTwin16, from 1975 to 1979. The details of these twin cohorts have been described previously [23–25]. All participants provided written informed consent. The study was approved by the Ethics Committee of the Helsinki University Central Hospital and the University of Southern California Health Sciences Campus Institutional Review Board.

Participants' demographics and self-reported lifetime smoking information, including age at initiation and cessation and quantity, were ascertained through structured questionnaires and interviews. Twins provided a baseline fasting blood sample, which was collected, processed and stored as serum at the time of enrollment. Monozygosity was confirmed using genetic markers.

2.2. Cotinine and Immune-Related Biomarker Measurement

Cotinine was measured from frozen serum samples using liquid chromatography/tandem mass spectrometry as previously described [26]. Thirty-nine immune related biomarkers capturing inflammation, B-cell activation and microbial translocation were measured in this study. Twelve biomarkers (IL1 beta [IL1b], IL2, IL5, IL13, IL17A, IL17F, IL22, IL23, interferon gamma [IFNg], IL4, IL10, IL12) were excluded due to undetectable results in at least 12% of the subjects. Twenty-seven biomarkers were included in the final analysis, representing inflammation-associated molecules (IL6, soluble IL6 receptor alpha [sIL6RA], IL8, IL18, IL1 receptor antagonist [IL1RA], interferon gamma-induced protein 10 [IP10/CXCL10], monocyte chemoattractant protein-1 [MCP1], soluble 130 kDa IL6 receptor glycoprotein [sgp130], tumor necrosis factor alpha [TNFA], soluble tumor necrosis factor alpha receptor type II [sTNFR2]), Th2-associated immune system molecules (B-cell activating factor [BAFF], C-C motif chemokine ligand 17 [CCL17]/thymus and activation regulated chemokine [TARC], C-C motif chemokine 22 [CCL22], C-C-C motif ligand 24 [CCL24], C-X-C motif chemokine ligand 13 [CXCL13], and soluble IL2R alpha [sIL2RA]) and microbial translocation (soluble CD14 [sCD14], sCD163, EndoCab IgM, fatty acid-binding protein 2 [FABP2], haptoglobin [HP], lipopolysaccharide binding protein [LBP]), and other functions (sCD30, FABP4, fibroblast growth factor 21 [FGF21], intercellular adhesion molecule 1 [ICAM1], IL15). All biomarkers, except HP and EndoCab, were measured using the Luminex xMAP system, which allowed the multiplexed simultaneous quantification of up to 100 biomarkers per panel, as previously described [15,21,27]. This system

uses spectrally addressed bead sets, each of which is conjugated with a different capture monoclonal antibody specific for a given target molecule. The bead mixtures were analyzed using a BioPlex 200 Luminex machine, to quantify the signal per bead address, and to provide levels of these analytes. Kits for the individual assays are from R & D Systems (Minneapolis, MN, USA). HP was measured with a standard ELISA assay from R & D Systems and EndoCab IgM was measured by ELISA from Hycult Biotech. Values below the detectable level, as provided by the assay instructions, were excluded in the analysis. Six biomarkers (CCL17/TARC, TNFA, FGF21, EndoCAB, HP and IL6) had undetectable levels in 0.7% to 11.9% of the specimens.

2.3. Statistical Analysis

The primary purpose of the analysis was to examine the effect of tobacco smoking on the levels of specific immune response proteins (biomarkers) related to lymphoma, using a set of matched twins to mitigate potential confounding for a more valid assessment of the effect. We assessed cigarette smoking exposure primarily using serum cotinine concentrations, with additional information on never and former smoking ascertained by self-report. Current smoking was defined as cotinine >3.08 ng/mL and non-current as cotinine ≤ 3.08 ng/mL based on previous studies [28]. Thirty-one twin pairs were discordant for current smoking and the remaining pairs were concordant for smoking status (30 pairs were concordant non-current smokers and 6 were concordant for current smoking, 4 with different amounts of smoking). We first assessed the association between current vs. non-current smoking status and each of the 27 biomarkers. We performed sensitivity analyses examining each of the 27 measurable biomarkers separately for never and former smokers compared to current smokers. We then retained only biomarkers that were significantly associated with current smoking status ($p < 0.05$) for further assessment. Classification of never and former smoking status was based on a self-report in the questionnaire and a serum cotinine ≤ 3.08 ng/mL (twins who reported that they were former smokers but had serum cotinine >3.08 ng/mL were re-classified to current smokers, assuming misreporting). We combined never and former smokers as a single reference group of “non-current smokers” for most analyses, unless otherwise specified, assuming that the effect of smoking on the immune system was not permanent and would occur in the setting of current, not past, exposure.

In subsequent analyses, we evaluated (1) whether smoking cessation and time since quitting impacted biomarker levels and (2) the dose–response relationship between serum cotinine and immune biomarker levels among current smokers. To assess a dose–response association between serum cotinine on biomarker levels, we further categorized current smokers (those with cotinine >3.08) into “lighter” vs. “heavier” cotinine based the median cotinine level (78.17 ng/mL) in our sample.

For the statistical analysis, we used linear mixed models, adjusting for twin pairs via an intercept, which provided both within and between twin pair information to estimate the beta coefficients and standard errors [29], equivalent to a paired *t*-test in linear regression [30]. By using MZ twins in this study, we have the added advantage of controlling for familial, in utero and other early life confounders not possible in a study of unrelated individuals. Age and sex were adjusted in the mixed models as fixed effects and a term for twin pair was included as a random effect, as previously described [9]. Biomarkers were log₂ transformed due to the skewed distribution except BAFF, CCL22, sCD14, sgp130 and IL15, because they had a normal distribution. We investigated adjustment for body mass index (BMI) given the correlation between smoking and obesity in prior studies [31,32] but did not find that BMI was related to smoking in our study and thus did not adjust for it in the mixed models. Least-squares (LS) means or geometric means were compared between smoking levels and *p* values were adjusted using Tukey’s multiple comparison method.

3. Results

The mean and median age of the participating twins were 37.3 years (SD: 18.9) and 24.8 years (range: 21.0–68.9), respectively (Table 1). More than half of the twins were females (56.7%) and most were non-current smokers (67.9%). Approximately 41% and 27% of twins were never and former smokers, respectively. Among former smokers, 44% of them had quit smoking more than 5 years ago. By twin pair, 36 (35.6%) were non-smokers/former smokers, 29 (28.7%) were non-smokers/current smokers, 16 (15.8%) were current smokers/former smokers, 18 (17.8%) were concordant for current smoking and 2 (2.0%) were concordant for former smoking.

Table 1. Characteristics of participating monozygotic (MZ) twins from the Finnish Twin Cohort Study.

Characteristics	Measure (SD or %)
	67 Twin Pairs
Mean Age (SD)	37.3 (18.9)
Female, N (%)	76 (56.7)
	134 Individual Twins
BMI kg/m ² , mean (SD)	25.0 (4.7)
Serum cotinine ng/mL, N (%)	
≤3.08 (Non-current smoking)	91 (67.9)
>3.08 (Current smoking)	
Low	22 (15.7)
High	21 (16.4)
Smoking status ¹ , N (%)	
Never	55 (41.0)
Former	36 (26.9)
Current	43 (32.1)
Years since quit among former smokers, N (%)	
≤5	20 (55.6)
>5	16 (44.4)

¹ Defined according to both serum cotinine and self-reported smoking status.

Out of the 27 immune-related biomarkers, 5 were significantly ($p < 0.05$) associated with current compared to non-current smoking: CCL17/TARC, sgp130, HP, BAFF and MCP1 (Figure 1 and Table S1).

The strongest association was seen for CCL17/TARC ($P_{\text{trend}} = 0.0001$), assessed in 85/91 participants. Twins who were current heavier smokers (defined by serum cotinine concentration above the median in this sample) had a mean CCL17/TARC level that was 52.4% higher than current lighter smoking twins ($P_{\text{adjusted}} = 0.006$), and 62.9% higher than non-current smoking twins ($P_{\text{adjusted}} = 0.0001$) (Table 2). Heavier smokers also had statistically significantly higher mean levels of BAFF (8.9%, $P_{\text{adjusted}} = 0.02$), haptoglobin (29.0%, $P_{\text{adjusted}} = 0.04$) and MCP1 (22.0%, $P_{\text{adjusted}} = 0.08$.) compared to current non-smokers (Table 2). In contrast, the mean sgp130 level for current heavier smokers was 6.3% lower than the mean level in non-current smokers ($P_{\text{adjusted}} = 0.03$) (Table 2). When immune biomarker levels were compared in heavier smokers to lighter smokers, and lighter smokers to non-current smokers, the directions of the associations were the same, but differences did not reach statistical significance (Table 2).




Figure 1. Associations between serum cotinine and each individual immune-related biomarker ($N = 27$). Cotinine levels (ng/mL) are defined as noncurrent (≤ 3.08) and current (> 3.08). Dots represent p values from mixed models assessing cotinine ($>$ vs. ≤ 3.08) and individual biomarker separately. Red dashed line represents $p = 0.05$.

Table 2. Differences in immune biomarker levels by smoking amount defined by serum cotinine concentration.

Smoking Level Comparison ¹	Difference in Least Squares Means ²	% Difference	p	P_{adj} ³
BAFF, pg/mL				
Current lighter smokers–Noncurrent	48.2	3.3	0.27	0.51
Current heavier smokers–Current lighter smokers	80.7	5.4	0.17	0.35
Current heavier smokers–Noncurrent	128.9	8.9	0.01	0.02
CCL17, pg/mL				
Current lighter smokers–Noncurrent	27.4	6.9	0.51	0.78
Current heavier smokers–Current lighter smokers	223.3	52.4	0.002	0.006
Current heavier smokers–Noncurrent	250.6	62.9	<0.0001	0.0001
Haptoglobin, ng/mL				
Current lighter smokers–Noncurrent	90.3	12.5	0.22	0.43
Current heavier smokers–Current lighter smokers	119.5	14.7	0.28	0.53
Current heavier smokers–Noncurrent	209.8	29.0	0.02	0.04
sgp130, ng/mL				
Current lighter smokers–Noncurrent	−10.0	−3.6	0.11	0.24
Current heavier smokers–Current lighter smokers	−7.5	−2.8	0.35	0.62
Current heavier smokers–Noncurrent	−17.5	−6.3	0.01	0.03
MCP1, pg/mL				
Current lighter smokers–Noncurrent	30.4	8.4	0.35	0.61
Current heavier smokers–Current lighter smokers	50.1	12.8	0.28	0.52
Current heavier smokers–Noncurrent	80.5	22.3	0.03	0.08

¹ For BAFF and sgp130, differences in means were presented; for CCL17/TARC, Haptoglobin and MCP1, differences in geometric means were presented. Means or geometric means were obtained from mixed models adjusted for age and sex. ² Serum cotinine levels (ng/mL): Non-current (cotinine ≤ 3.08), current lighter smokers (cotinine: 3.08–78.17), current heavier smokers (cotinine > 78.17). ³ p -values adjusted using Tukey’s method for multiple comparison adjustment.

We observed a significant dose–response relationship between smoking levels (current heavier, current lighter and non-current smoking) and the five biomarker levels ($P_{\text{trend}} < 0.05$; Table S2). Circulating levels of the five immune biomarkers among self-reported former smokers were not significantly different from those in never smokers (Table S3a); however, they were significantly different compared to those in current smokers (Table S3b). When former smokers were examined in further detail, a trend was observed between years since quitting and levels of CCL17/TARC (positive) and sgp130 (inverse) ($P_{\text{trend}} < 0.05$; Table S4). There was a similar but borderline significant trend for BAFF ($P_{\text{trend}} = 0.08$; Table S4). Former smokers who quit more than five years ago had geometric mean CCL17/TARC levels similar to those of never smokers, while those who quit more recently had levels that were intermediate between never smokers and current smokers ($P_{\text{trend}} = 0.01$) (Figure 2). Former smokers generally had sgp130 and BAFF levels that were intermediate between never and current smokers; however, the differences by time since quitting were not as evident.




Figure 2. Associations between smoking status and biomarker levels: (a) CCL17/TARC ($P_{\text{trend}} = 0.01$); (b) sgp130 ($P_{\text{trend}} = 0.01$); (c) BAFF ($P_{\text{trend}} = 0.08$). Smoking status and years since quit were self-reported; however, twin pairs with discordance in self-reports and serum cotinine levels were excluded from analysis. Points represent means (BAFF and sgp130) or geometric means (CCL17/TARC) of biomarker levels and solid lines represent 95% confidence interval (CI).

There was a significant trend for immune biomarker levels according to the duration of smoking (≤ 5 years, >5 years), with the exception of MCP1 (Table S5). Relative to the reference group of non-current smokers, beta values were increased in longer duration compared to shorter duration smokers. All five immune biomarkers were significantly associated with self-reported smoking of ≥ 10 cigarettes per day but not with < 10 cigarettes per day (Table S6), consistent with observations when serum cotinine concentration above and below the median concentration was used to define heavier and lighter smoking. There was a moderate positive correlation between HP and BAFF (Pearson $r = 0.26$, $p < 0.05$) and CCL17/TARC (Pearson $r = 0.2$, $p < 0.05$) (Figure S1), but not between the other biomarkers.

We examined the intra-pair correlation coefficient (ICC) for the 27 biomarkers among the 67 MZ twin pairs and observed that approximately 60% of the biomarkers demonstrated ICC > 0.5 (Table S7). Of the five immune biomarkers identified in this study, CCL17/TARC, BAFF and sGP130 all showed an ICC > 0.5 while haptoglobin and MCP1 demonstrated a lower ICC (ranging from 0.28–0.44). Specifically, the ICC for CCL17/TARC was 0.66 (95%CI: 0.50–0.78).

4. Discussion

Immune responses, nicotine metabolism pathways and smoking behaviors are at least partially heritable [33–35]. We took advantage of natural genetic matching in addition to age-, sex-, early life in twins to conduct a unique study to examine the effect of an

exposure (smoking) on immune biomarkers related to lymphoma. To enhance the validity of the matched comparison and limit confounding by genetics, we limited the study to MZ twins only. We found that current smoking status, defined by serum cotinine levels, was significantly associated with serum levels of markers related to inflammation and macrophage activation (MCP1 and sgp130), Th2 immune response (CCL17/TARC and BAFF) and microbial translocation (haptoglobin) pathways, markers that are associated with both HL and NHL [15,21,36]. For several of these markers, including CCL17/TARC, levels among former smokers who stopped smoking over 5 years ago were similar to those in never-smokers, suggesting that smoking cessation may lead to a reversal of smoking-induced biomarker alterations. We did not observe differences in innate inflammatory immune biomarkers including IL8, TNF α and sTNFR2, consistent with a previous study that examined these factors in 22 pairs of smoking-discordant twins [10] (other soluble markers associated with HL, FL and microbial translocation examined in our study were not examined in this previous twin study).

Although our numbers were small, the results were statistically significant and there was strong biological plausibility. The strongest association we observed was between current smoking and increased CCL17/TARC levels, consistent with results from a prior nested case–control study of unrelated individuals [37]. In that study, smokers had a four-fold increased risk of high serum CCL17/TARC levels compared to non-smokers, but no dose–response association with cigarettes per day was observed [37]. In an experimental animal model of allergic asthma, exposure to cigarette smoke induced CCL17/TARC production and secretion in macrophages from bronchial lavage, evidence that smoke exposure appears to be causing the increase in CCL17/TARC [38]. CCL17/TARC is a confirmed biomarker for HL, is highly expressed by the neoplastic Hodgkin–Reed–Sternberg (HRS) cells with elevated levels found in the majority of HL patients [39,40]. Smoking is associated with an increased risk of overall HL, and even more strongly associated with mixed cellularity and EBV+ subtypes [2,3]. Our results, along with the previous study of unrelated individuals [37], suggest that the higher levels of CCL17/TARC in smokers may contribute to the association between HL and smoking.

Three of the other four markers (MCP1, BAFF and haptoglobin) were positively associated with smoking and one (sgp130) was inversely associated. MCP1, HP and BAFF are linked to smoking in specific disease contexts and different tissues (e.g., bronchial secretions [41–43], and sgp130 has been linked indirectly to smoking via the STAT3 transcription factor pathway and modulation of tobacco carcinogen induced lung cancer [44]. There is experimental evidence that smoking can induce MCP1, CCL17/TARC, BAFF production, primarily in macrophages [38,43,45]. Thus, there is previous evidence suggesting that smoking can activate these cytokines/chemokines in macrophages, which could then promote B-cell activation, leading to lymphomagenesis.

Haptoglobin is a molecule produced in lung tissue (among others) that binds to hemoglobin and thus decreases oxygenation. Its target is CD163 on macrophages, where it induces phagocytosis to remove it from tissues to limit damage from free heme [46]. The association between elevated levels of haptoglobin and smoking suggests that perhaps that injury to the alveolar membranes results in increased secretion of this acute phase protein. Elevated levels of this marker predict AIDS-associated non-Hodgkin lymphoma in the setting of microbial translocation, where Gram-negative bacteria leak into the bloodstream from damaged intestinal epithelium [47]. Other immune markers associated with microbial translocation were not associated with smoking in this study, providing little support for this pathway.

Levels of CCL17/TARC, sgp130 and BAFF in those who quit smoking over five years ago were similar to those who never smoked, suggesting the effect of smoking on these biomarkers is not permanent. This is consistent with the epidemiological observation that current, but not former, smokers had an increased risk of HL [2]. In an earlier study, the same group found that risk of HL decreased significantly as time since quitting increased [48]. For follicular lymphoma, the 10% increased risk associated with smoking

appears to be maintained for the first 10 years after quitting, but then risk decreases slowly after that [4]. Larger longitudinal studies that assess the biomarker changes corresponding to smoking cessation are warranted to better characterize the trajectories of smoking cessation on biomarker levels.

Our study has several strengths. A major advantage is the use of genetically identical twin pairs as the study population (i.e., within-pair analyses, see Methods). Circulating immune-related markers can be influenced by genetic variation [49]; thus, adjustment for twin pair can control for the genetic factors in the assessment of the smoking and biomarker association. Of the 27 biomarkers examined in this study, 60% demonstrated ICC >0.5 in all the MZ twin pairs, suggesting at least moderate genetic influence on the biomarker levels. CCL17/TARC, the strongest association identified in this study, showed an ICC 0.66 (95%CI: 0.50–0.78). Thus, using genetically identical twin pairs as study population made it possible to control for genetic influence on biomarker levels. Moreover, inherent matching on parental smoke exposure, age and sex in twins controls for additional confounding. Another strength of our study is the use of serum cotinine concentration to quantify current exposure to tobacco [28], more objectively assessing current smoking compared to self-reported tobacco use (although some analyses showed similar results for cotinine and self-reported smoking amount). Finally, we conducted a novel comprehensive investigation of the effects of smoking on lymphoma-associated circulating immune-related markers.

Our study also has several limitations, especially small sample size for smoking concordant twin pairs, which precluded a more detailed assessment of the dose–response effect of cumulative smoking exposure (e.g., years of smoking) on circulating immune biomarker levels. Because the subjects were all Finnish twins of European origin, the lack of cultural, racial and ethnic diversity limits generalizability. Racial/ethnic differences in nicotine metabolism are well established and slow metabolizers are uncommon in populations of European origin [28]. Some systemic inflammatory markers, such as C-reactive protein, vary by racial and ethnic groups [50]. Nevertheless, our study provides new information that can be validated in other groups in the future.

5. Conclusions

In conclusion, our results suggest that current smoking may be associated with altered levels of immune proteins associated with B-cell and macrophage activation and immune cell trafficking that could explain the association between HL, and possibly FL, and smoking. The strongest association was between current smoking and higher circulating levels of TARC/CCL17, an established HL disease biomarker. Importantly, levels of the 5 significantly associated immune proteins were similar in never smokers and those who had long since quit smoking, suggesting a relatively short-term effect of tobacco on the immune system. We previously demonstrated an association between smoking and levels of Th2 proteins (IL-4, IL-5 and IL-13) secreted in supernatant from PHA-stimulated T-cells in smoking discordant twins [9], an artificial system. We also showed that current and former smokers had higher persistent antibody levels to *C. pneumoniae*-specific serum IgA compared to their non-smoking twins [51], but the immune response was in the context of a specific infection. To our knowledge, the present study is the first that demonstrates an elevation of immune proteins relevant to lymphomagenesis in serum from genetically matched twin smokers and non-smokers.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/cancers13215395/s1>, Table S1: The association between serum cotinine defined smoking status (non-current vs. current) and biomarker levels, Table S2: The association of serum cotinine and immune biomarkers levels, Table S3: The association between smoking status (never/former/current) and serum immune biomarker levels. Never smokers (a) or former smokers (b) were used as reference group, Table S4: The association of self-reported smoking status and serum immune biomarkers levels, Table S5: The association of years of smoking and serum immune biomarkers levels, Table S6: The association of cigarettes per day (CPD) and serum immune biomarkers levels, Table S7: Biomarker

intra-pair correlation coefficient (ICC) in the 67 MZ twin pairs, Figure S1: Pearson correlation of serum biomarkers.

Author Contributions: W.C., J.K. and O.M.-M. conceived of the study and hypotheses. R.F.T. conducted cotinine assays and provided guidance on interpretation of results and classification of smokers. M.E. and L.M. designed, conducted, and interpreted immune biomarker assays. M.O. and A.E.H. organized the data and sample collection from the twins. T.M.M. and J.K. maintain the twin registries. D.V.C. designed the statistical analysis and J.W. conducted the statistical analysis. J.W. and W.C. wrote the manuscript. All co-authors reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was undertaken, in part, thanks to funding from the Canada Research Chairs program (R.F.T.), a Canadian Institutes of Health Research Foundation grant FDN-154294 (to R.F.T.) and the Centre for Addiction and Mental Health (to R.F.T.). Data collection and analyses of the Finnish twin data have been supported by the Academy of Finland (grants 265240, 263278, 308248, 312073, 336823 to J.K.) and the Sigrid Juselius Foundation (to J.K.). This work was further supported by the University of Southern California, Norris Comprehensive Cancer Center gift account (to W.C.) and STOP CANCER award (to W.C.), and the California Tobacco Disease-Related Program (RT-01077H, 6RT-0354H to T.M.M.).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. Data collection for the Finnish Twin Cohort has been approved by the Hospital District of Helsinki and Uusimaa, the ethics committee for epidemiology and public health (HUS-113-E3-01, HUS-346-E0-05, HUS 136/E3/01, HUS 270/13/03/01/2008, HUS 154/13/03/00/11). The study was approved by the University of Southern California Health Sciences Campus Institutional Review Board HS-16-00187).

Informed Consent Statement: Written informed consent was obtained from all subjects who gave DNA samples in accordance with the current edition of the Declaration of Helsinki and the collection of blood samples followed the recommendations given in the Declaration of Helsinki and its amendments.

Data Availability Statement: The twin dataset used in the current study will be located in the Biobank of the National Institute for Health and Welfare, Finland. All the biobanked data are publicly available for use by qualified researchers following a standardized application procedure (<https://thl.fi/en/web/thl-biobank/for-researchers> accessed on 25 November 2021).

Acknowledgments: We would like to acknowledge Jose Aparicio and Manuel Garcia with assistance with samples and the participating twins for their time and effort.

Conflicts of Interest: R.F.T. has consulted for Quinn Emanuel and Ethismos Research Inc on unrelated topics.

References

1. Vineis, P.; Alavanja, M.; Buffler, P.; Fontham, E.; Franceschi, S.; Gao, Y.; Gupta, P.C.; Hackshaw, A.; Matos, E.; Samet, J.; et al. Tobacco and cancer: Recent epidemiological evidence. *J. Natl. Cancer Inst.* **2004**, *96*, 99–106. [[CrossRef](#)] [[PubMed](#)]
2. Kamper-Jørgensen, M.; Rostgaard, K.; Glaser, S.; Zahm, S.; Cozen, W.; Smedby, K.; Sanjosé, S.; Chang, E.; Zheng, T.; La Vecchia, C.; et al. Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: A pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). *Ann. Oncol.* **2013**, *24*, 2245–2255. [[CrossRef](#)] [[PubMed](#)]
3. Cozen, W.; Hamilton, A.; Zhao, P.; Salam, M.; Deapen, D.; Nathwani, B.; Weiss, L.M.; Mack, T.M. A protective role for early childhood exposures and young adult Hodgkin lymphoma. *Blood J. Am. Soc. Hematol.* **2009**, *114*, 4014–4020.
4. Morton, L.M.; Hartge, P.; Holford, T.R.; Holly, E.A.; Chiu, B.C.; Vineis, P.; Stagnaro, E.; Willett, E.V.; Franceschi, S.; La Vecchia, C.; et al. Cigarette smoking and risk of non-Hodgkin lymphoma: A pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). *Cancer Epidemiol. Biomark. Prev.* **2005**, *14*, 925–933. [[CrossRef](#)]
5. Gern, J.E.; Lemanske, R.F.; Busse, W.W. Early life origins of asthma. *J. Clin. Invest.* **1999**, *104*, 837–843. [[CrossRef](#)]
6. Wurster, A.; Rodgers, V.; White, M.; Rothstein, T.; Grusby, M. Interleukin-4-mediated protection of primary B cells from Apoptosis through Stat6-dependent Up-regulation of Bcl-xL. *J. Biol. Chem.* **2002**, *277*, 27169–27175. [[CrossRef](#)]
7. Noakes, P.S.; Holt, P.G.; Prescott, S.L. Maternal smoking in pregnancy alters neonatal cytokine responses. *Allergy* **2003**, *58*, 1053–1058. [[CrossRef](#)] [[PubMed](#)]
8. Byron, K.A.; Varigos, G.A.; Wootton, A.M. IL-4 production is increased in cigarette smokers. *Clin. Exp. Immunol.* **1994**, *95*, 333–336. [[CrossRef](#)]

9. Cozen, W.; Diaz-Sanchez, D.; James Gauderman, W.; Zadnick, J.; Cockburn, M.; Gill, P.; Masood, R.; Hamilton, A.S.; Jyrala, M.; Mack, T.M. Th1 and Th2 cytokines and IgE levels in identical twins with varying levels of cigarette consumption. *J. Clin. Immunol.* **2004**, *24*, 617–622. [[CrossRef](#)] [[PubMed](#)]
10. Andreoli, C.; Bassi, A.; Gregg, E.O.; Nunziata, A.; Puntoni, R.; Corsini, E. Effects of cigarette smoking on circulating leukocytes and plasma cytokines in monozygotic twins. *Clin. Chem. Lab. Med.* **2015**, *53*, 57–64. [[CrossRef](#)]
11. Cozen, W.; Gill, P.; Salam, M.; Nieter, A.; Masood, R.; Cockburn, M.; Gauderman, W.J.; Martinez-Maza, O.; Nathwani, B.N.; Pike, M.C.; et al. Interleukin-2, interleukin-12 and interferon- γ levels and risk of young adult Hodgkin lymphoma. *Blood J. Am. Soc. Hematol.* **2008**, *111*, 3377–3382. [[CrossRef](#)]
12. Cozen, W.; Timofeeva, M.; Li, D.; Diepstra, A.; Hazelett, D.; Delahaye-Sourdeix, M.; Edlund, C.K.; Franke, L.; Rostgaard, K.; Van Den Berg, D.J.; et al. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. *Nat. Comm.* **2014**, *25*, 3856. [[CrossRef](#)] [[PubMed](#)]
13. Steidl, C.; Lee, T.; Shah, S.P.; Farinha, P.; Han, G.; Nayar, T.; Delaney, A.; Jones, S.J.; Iqbal, J.; Weisenburger, D.D.; et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *N. Engl. J. Med.* **2010**, *362*, 875–885. [[CrossRef](#)]
14. Grulich, A.E.; Vajdic, C.; Cozen, W. Altered immunity as a risk factor for non-hodgkin lymphoma. *Cancer Epidemiol. Biomark. Prev.* **2007**, *16*, 405–408. [[CrossRef](#)] [[PubMed](#)]
15. De Roos, A.; Mirick, D.; Edlefsen, K.; LaCroix, A.; Kopecky, K.; Madeleine, M.; Magpantay, L.; Martinez-Maza, O. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. *Cancer Res.* **2012**, *72*, 4733–4743. [[CrossRef](#)]
16. Sauer, M.; Plütschow, A.; Jachimowicz, R.D.; Kleefisch, D.; Reiners, K.S.; Ponader, S.; Engert, A.; von Strandmann, E.P. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. *Am. J. Hematol.* **2012**, *88*, 113–115. [[CrossRef](#)] [[PubMed](#)]
17. Van der Weyden, C.; Pileri, S.; Feldman, A.; Whisstock, J.; Prince, H. Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions. *Blood Cancer J.* **2017**, *7*, e603. [[CrossRef](#)] [[PubMed](#)]
18. Cozen, W.; Gill, P.S.; Ingles, S.A.; Masood, R.; Martínez-Maza, O.; Cockburn, M.G.; Gauderman, W.J.; Pike, M.C.; Bernstein, L.; Nathwani, B.N.; et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. *Blood* **2004**, *103*, 3216–3221. [[CrossRef](#)] [[PubMed](#)]
19. Xu, H.; Liew, L.N.; Kuo, I.C.; Huang, C.H.; Goh, D.L.-M.; Chua, K.Y. The modulatory effects of lipopolysaccharide-stimulated B cells on differential T-cell polarization. *Immunology* **2008**, *125*, 218–228. [[CrossRef](#)] [[PubMed](#)]
20. Brinkhoff, A.; Zeng, Y.; Sieberichs, A.; Dolff, S.; Shilei, X.; Sun, M.; Engler, H.; Benson, S.; Korth, J.; Schedlowski, M.; et al. B-cell dynamics during experimental endotoxemia in humans. *Biosci. Rep.* **2019**, *39*, BSR20182347. [[CrossRef](#)] [[PubMed](#)]
21. Epeldegui, M.; Magpantay, L.; Guo, Y.; Halec, G.; Cumberland, W.G.; Yen, P.K.; Macatangay, B.; Margolick, J.B.; Rositch, A.F.; Wolinsky, S.; et al. A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma. *AIDS* **2018**, *32*, 945–954. [[CrossRef](#)] [[PubMed](#)]
22. Jungnickel, C.; Wonnenberg, B.; Karabiber, O.; Wolf, A.; Voss, M.; Wolf, L.; Honecker, A.; Kamyschnikow, A.; Herr, C.; Bals, R.; et al. Cigarette smoke-induced disruption of pulmonary barrier and bacterial translocation drive tumor-associated inflammation and growth. *Am. J. Physiol. Cell. Mol. Physiol.* **2015**, *309*, L605–L613. [[CrossRef](#)] [[PubMed](#)]
23. Rose, R.J.; Salvatore, J.E.; Aaltonen, S.; Barr, P.B.; Bogl, L.H.; Byers, H.A.; Heikkilä, K.; Korhonen, T.; Latvala, A.; Palviainen, T.; et al. FinnTwin12 cohort: An updated review. *Twin Res. Hum. Genet.* **2019**, *22*, 302–311. [[CrossRef](#)] [[PubMed](#)]
24. Kaprio, J.; Bollepalli, S.; Buchwald, J.; Iso-Markku, P.; Korhonen, T.; Kovanen, V.; Kujala, U.; Laakkonen, E.K.; Latvala, A.; Leskinen, T.; et al. The older finnish twin cohort—45 years of follow-up. *Twin Res. Hum. Genet.* **2019**, *22*, 240–254. [[CrossRef](#)] [[PubMed](#)]
25. Kaidesoja, M.; Aaltonen, S.; Bogl, L.; Heikkilä, K.; Kaartinen, S.; Kujala, U.; Kärkkäinen, U.; Masip, G.; Mustelin, L.; Palviainen, T.; et al. FinnTwin16: A longitudinal study from age 16 of a population-based Finnish twin cohort. *Twin. Res. Hum. Genet.* **2019**, *22*, 530–539. [[CrossRef](#)] [[PubMed](#)]
26. Tanner, J.-A.; Novalen, M.; Jatlow, P.; Huestis, M.A.; Murphy, S.E.; Kaprio, J.; Kankaanpää, A.; Galanti, L.; Stefan, C.; George, T.P.; et al. Nicotine metabolite ratio (3-Hydroxycotinine/Cotinine) in plasma and urine by different analytical methods and laboratories: Implications for clinical implementation. *Cancer Epidemiol. Biomark. Prev.* **2015**, *24*, 1239–1246. [[CrossRef](#)] [[PubMed](#)]
27. Epstein, M.M.; Breen, E.C.; Magpantay, L.; Detels, R.; Lepone, L.; Penugonda, S.; Bream, J.; Jacobson, L.P.; Martínez-Maza, O.; Birmann, B.M. Temporal stability of serum concentrations of cytokines and soluble receptors measured across two years in low-risk HIV-seronegative men. *Cancer Epidemiol. Biomark. Prev.* **2013**, *22*, 2009–2015. [[CrossRef](#)] [[PubMed](#)]
28. Benowitz, N.L.; Bernert, J.T.; Caraballo, R.S.; Holiday, D.B.; Wang, J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. *Am. J. Epidemiol.* **2008**, *169*, 236–248. [[CrossRef](#)]
29. Bates, D.; Mächler, M.; Bolker, B.; Walker, S. Fitting linear mixed-effects models using lme4. *J. Stat. Softw.* **2015**, *67*, 48. [[CrossRef](#)]
30. Maxwell, S.; Delaney, H.D.; Kelley, K. *Designing Experiments and Analyzing Data: A Model Comparison Perspective*, 3rd ed.; Routledge: New York, NY, USA, 2017.
31. Dare, S.; Mackay, D.; Pell, J. Relationship between smoking and obesity: A cross-sectional study of 499,504 middle-aged adults in the UK general population. *PLoS ONE* **2015**, *10*, e0123579. [[CrossRef](#)] [[PubMed](#)]

32. Piirtola, M.; Jelenkovic, A.; Latvala, A.; Sund, R.; Honda, C.; Inui, F.; Watanabe, M.; Tomizawa, R.; Iwatani, Y.; Ordoñana, J.R.; et al. Association of current and former smoking with body mass index: A study of smoking discordant twin pairs from 21 twin cohorts. *PLoS ONE* **2018**, *13*, e0200140. [[CrossRef](#)] [[PubMed](#)]
33. Buchwald, J.; Chenoweth, M.J.; Palviainen, T.; Zhu, G.; Benner, C.; Gordon, S.; Korhonen, T.; Ripatti, S.; Madden, P.A.F.; Lehtimäki, T.; et al. Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. *Mol. Psychiatry* **2021**, *26*, 2212–2223. [[CrossRef](#)] [[PubMed](#)]
34. Hamilton, A.S.; Lessov-Schlaggar, C.N.; Cockburn, M.G.; Unger, J.B.; Cozen, W.; Mack, T.M. Gender differences in determinants of smoking initiation and persistence in California Twins. *Cancer Epidemiol. Biomark. Prev.* **2006**, *15*, 1189–1197. [[CrossRef](#)] [[PubMed](#)]
35. Mangino, M.; Roederer, M.; Beddall, M.H.; Nestle, F.O.; Spector, T.D. Innate and adaptive immune traits are differentially affected by genetic and environmental factors. *Nat. Commun.* **2017**, *8*, 13850. [[CrossRef](#)] [[PubMed](#)]
36. Yang, S.; Li, J.-Y.; Xu, W. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. *Crit. Rev. Oncol.* **2014**, *91*, 113–122. [[CrossRef](#)] [[PubMed](#)]
37. Shiels, M.S.; Katki, H.A.; Freedman, N.D.; Purdue, M.; Wentzensen, N.; Trabert, B.; Kitahara, C.M.; Furr, M.; Li, Y.; Kemp, T.J.; et al. Cigarette smoking and variations in systemic immune and inflammation markers. *J. Natl. Cancer Inst.* **2014**, *106*, dju294. [[CrossRef](#)]
38. Ritter, M.; Göggel, R.; Chaudhary, N.; Wiedenmann, A.; Jung, B.; Weith, A.; Seither, P. Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation. *Biochem. Biophys. Res. Commun.* **2005**, *334*, 254–262. [[CrossRef](#)]
39. Van den Berg, A.; Visser, L.; Poppema, S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. *Am. J. Pathol.* **1999**, *154*, 1685–1691. [[CrossRef](#)]
40. Plattel, W.J.; Berg, A.V.D.; Visser, L.; Van Der Graaf, A.-M.; Pruijm, J.; Vos, H.; Hepkema, B.; Diepstra, A.; Van Imhoff, G.W. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. *Haematologica* **2011**, *97*, 410–415. [[CrossRef](#)] [[PubMed](#)]
41. Al-Bayaty, F.H.; Baharuddin, N.; Abdulla, M.A.; Ali, H.M.; Arkilla, M.B.; Albayaty, M.F. The influence of cigarette smoking on gingival bleeding and serum concentrations of haptoglobin and Alpha 1-Antitrypsin. *BioMed Res. Int.* **2013**, *2013*, 684154. [[CrossRef](#)] [[PubMed](#)]
42. Komiyama, M.; Takanabe, R.; Ono, K.; Shimada, S.; Wada, H.; Yamakage, H.; Satoh-Asahara, N.; Morimoto, T.; Shimatsu, A.; Takahashi, Y.; et al. Association between monocyte chemoattractant protein-1 and blood pressure in smokers. *J. Int. Med. Res.* **2017**, *46*, 965–974. [[CrossRef](#)] [[PubMed](#)]
43. Morissette, M.C.; Gao, Y.; Shen, P.; Thayaparan, D.; Bérubé, J.-C.; Paré, P.D.; Brandsma, C.-A.; Hao, K.; Bossé, Y.; Ettinger, R.; et al. Role of BAFF in pulmonary autoantibody responses induced by chronic cigarette smoke exposure in mice. *Physiol. Rep.* **2016**, *4*, e13057. [[CrossRef](#)] [[PubMed](#)]
44. Miller, A.; Brooks, G.D.; McLeod, L.; Ruwanpura, S.; Jenkins, B. Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis. *Oncogene* **2014**, *34*, 1510–1519. [[CrossRef](#)] [[PubMed](#)]
45. Kastelein, T.; Duffield, R.; Marino, F. Human insitu cytokine and leukocyte responses to acute smoking. *J. Immunotoxicol.* **2017**, *14*, 109–115. [[CrossRef](#)] [[PubMed](#)]
46. Thomsen, J.H.; Etzerodt, A.; Svendsen, P.; Moestrup, S.K. The Haptoglobin-CD163-Heme Oxygenase-1 Pathway for Hemoglobin Scavenging. *Oxidative Med. Cell. Longev.* **2013**, *2013*, 523652. [[CrossRef](#)] [[PubMed](#)]
47. Epeldegui, M.; Hussain, S. The role of microbial translocation and immune activation in AIDS-associated non-Hodgkin lymphoma pathogenesis: What have we learned? *Crit. Rev. Immunol.* **2020**, *40*, 41–51. [[CrossRef](#)] [[PubMed](#)]
48. Hjalgrim, H.; Ekström-Smedby, K.; Rostgaard, K.; Amini, R.-M.; Molin, D.; Hamilton-Dutoit, S.; Schöllkopf, C.; Chang, E.T.; Ralfkiaer, E.; Adami, H.-O.; et al. Cigarette smoking and risk of Hodgkin lymphoma: A population-based case-control study. *Cancer Epidemiol. Biomark. Prev.* **2007**, *16*, 1561–1566. [[CrossRef](#)] [[PubMed](#)]
49. Ahola-Olli, A.V.; Würtz, P.; Havulinna, A.S.; Aalto, K.; Pitkänen, N.; Lehtimäki, T.; Kähönen, M.; Lyytikäinen, L.-P.; Raitoharju, E.; Seppälä, I.; et al. Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. *Am. J. Hum. Genet.* **2016**, *100*, 40–50. [[CrossRef](#)] [[PubMed](#)]
50. Kelley-Hedgpeath, A.; Lloyd-Jones, D.M.; Colvin, A.; Matthews, K.A.; Johnston, J.; Sowers, M.R.; Sternfeld, B.; Pasternak, R.C.; Chae, C.U. Ethnic differences in C-reactive protein concentrations. *Clin. Chem.* **2008**, *54*, 1027–1037. [[CrossRef](#)] [[PubMed](#)]
51. Von Hertzen, L.; Surcel, H.; Kaprio, J.; Koskenvuo, M.; Bloigu, A.; Leinonen, M.; Saikku, P. Immune responses to Chlamydia pneumoniae in twins in relation to gender and smoking. *J. Med. Microbiol.* **1998**, *47*, 441–446. [[CrossRef](#)] [[PubMed](#)]